2024-12-012026-03-312026-03-31false14488452SOLIHULL HEALTHCARE PROPCO LIMITED2026-09-23falseiso4217:GBPxbrli:pure144884522024-11-30144884522026-03-31144884522024-12-012026-03-31144884522023-11-30144884522024-11-30144884522023-12-012024-11-3014488452bus:SmallEntities2024-12-012026-03-3114488452bus:AuditExempt-NoAccountantsReport2024-12-012026-03-3114488452bus:FullAccounts2024-12-012026-03-3114488452bus:PrivateLimitedCompanyLtd2024-12-012026-03-3114488452core:WithinOneYear2026-03-3114488452core:AfterOneYear2026-03-3114488452core:WithinOneYear2024-11-3014488452core:AfterOneYear2024-11-3014488452core:ShareCapital2026-03-3114488452core:SharePremium2026-03-3114488452core:RevaluationReserve2026-03-3114488452core:OtherReservesSubtotal2026-03-3114488452core:RetainedEarningsAccumulatedLosses2026-03-3114488452core:ShareCapital2024-11-3014488452core:SharePremium2024-11-3014488452core:RevaluationReserve2024-11-3014488452core:OtherReservesSubtotal2024-11-3014488452core:RetainedEarningsAccumulatedLosses2024-11-3014488452core:LandBuildings2026-03-3114488452core:PlantMachinery2026-03-3114488452core:Vehicles2026-03-3114488452core:FurnitureFittings2026-03-3114488452core:OfficeEquipment2026-03-3114488452core:NetGoodwill2026-03-3114488452core:IntangibleAssetsOtherThanGoodwill2026-03-3114488452core:ListedExchangeTraded2026-03-3114488452core:UnlistedNon-exchangeTraded2026-03-3114488452core:LandBuildings2024-11-3014488452core:PlantMachinery2024-11-3014488452core:Vehicles2024-11-3014488452core:FurnitureFittings2024-11-3014488452core:OfficeEquipment2024-11-3014488452core:NetGoodwill2024-11-3014488452core:IntangibleAssetsOtherThanGoodwill2024-11-3014488452core:ListedExchangeTraded2024-11-3014488452core:UnlistedNon-exchangeTraded2024-11-3014488452core:LandBuildings2024-12-012026-03-3114488452core:PlantMachinery2024-12-012026-03-3114488452core:Vehicles2024-12-012026-03-3114488452core:FurnitureFittings2024-12-012026-03-3114488452core:OfficeEquipment2024-12-012026-03-3114488452core:NetGoodwill2024-12-012026-03-3114488452core:IntangibleAssetsOtherThanGoodwill2024-12-012026-03-3114488452core:ListedExchangeTraded2024-12-012026-03-3114488452core:UnlistedNon-exchangeTraded2024-12-012026-03-3114488452core:MoreThanFiveYears2024-12-012026-03-3114488452core:Non-currentFinancialInstruments2026-03-3114488452core:Non-currentFinancialInstruments2024-11-3014488452dpl:CostSales2024-12-012026-03-3114488452dpl:DistributionCosts2024-12-012026-03-3114488452core:LandBuildings2024-12-012026-03-3114488452core:PlantMachinery2024-12-012026-03-3114488452core:Vehicles2024-12-012026-03-3114488452core:FurnitureFittings2024-12-012026-03-3114488452core:OfficeEquipment2024-12-012026-03-3114488452dpl:AdministrativeExpenses2024-12-012026-03-3114488452core:NetGoodwill2024-12-012026-03-3114488452core:IntangibleAssetsOtherThanGoodwill2024-12-012026-03-3114488452dpl:GroupUndertakings2024-12-012026-03-3114488452dpl:ParticipatingInterests2024-12-012026-03-3114488452dpl:GroupUndertakingscore:ListedExchangeTraded2024-12-012026-03-3114488452core:ListedExchangeTraded2024-12-012026-03-3114488452dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-12-012026-03-3114488452core:UnlistedNon-exchangeTraded2024-12-012026-03-3114488452dpl:CostSales2023-12-012024-11-3014488452dpl:DistributionCosts2023-12-012024-11-3014488452core:LandBuildings2023-12-012024-11-3014488452core:PlantMachinery2023-12-012024-11-3014488452core:Vehicles2023-12-012024-11-3014488452core:FurnitureFittings2023-12-012024-11-3014488452core:OfficeEquipment2023-12-012024-11-3014488452dpl:AdministrativeExpenses2023-12-012024-11-3014488452core:NetGoodwill2023-12-012024-11-3014488452core:IntangibleAssetsOtherThanGoodwill2023-12-012024-11-3014488452dpl:GroupUndertakings2023-12-012024-11-3014488452dpl:ParticipatingInterests2023-12-012024-11-3014488452dpl:GroupUndertakingscore:ListedExchangeTraded2023-12-012024-11-3014488452core:ListedExchangeTraded2023-12-012024-11-3014488452dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-12-012024-11-3014488452core:UnlistedNon-exchangeTraded2023-12-012024-11-3014488452core:NetGoodwill2026-03-3114488452core:IntangibleAssetsOtherThanGoodwill2026-03-3114488452core:LandBuildings2026-03-3114488452core:PlantMachinery2026-03-3114488452core:Vehicles2026-03-3114488452core:FurnitureFittings2026-03-3114488452core:OfficeEquipment2026-03-3114488452core:AfterOneYear2026-03-3114488452core:WithinOneYear2026-03-3114488452core:ListedExchangeTraded2026-03-3114488452core:UnlistedNon-exchangeTraded2026-03-3114488452core:ShareCapital2026-03-3114488452core:SharePremium2026-03-3114488452core:RevaluationReserve2026-03-3114488452core:OtherReservesSubtotal2026-03-3114488452core:RetainedEarningsAccumulatedLosses2026-03-3114488452core:NetGoodwill2024-11-3014488452core:IntangibleAssetsOtherThanGoodwill2024-11-3014488452core:LandBuildings2024-11-3014488452core:PlantMachinery2024-11-3014488452core:Vehicles2024-11-3014488452core:FurnitureFittings2024-11-3014488452core:OfficeEquipment2024-11-3014488452core:AfterOneYear2024-11-3014488452core:WithinOneYear2024-11-3014488452core:ListedExchangeTraded2024-11-3014488452core:UnlistedNon-exchangeTraded2024-11-3014488452core:ShareCapital2024-11-3014488452core:SharePremium2024-11-3014488452core:RevaluationReserve2024-11-3014488452core:OtherReservesSubtotal2024-11-3014488452core:RetainedEarningsAccumulatedLosses2024-11-3014488452core:NetGoodwill2023-11-3014488452core:IntangibleAssetsOtherThanGoodwill2023-11-3014488452core:LandBuildings2023-11-3014488452core:PlantMachinery2023-11-3014488452core:Vehicles2023-11-3014488452core:FurnitureFittings2023-11-3014488452core:OfficeEquipment2023-11-3014488452core:AfterOneYear2023-11-3014488452core:WithinOneYear2023-11-3014488452core:ListedExchangeTraded2023-11-3014488452core:UnlistedNon-exchangeTraded2023-11-3014488452core:ShareCapital2023-11-3014488452core:SharePremium2023-11-3014488452core:RevaluationReserve2023-11-3014488452core:OtherReservesSubtotal2023-11-3014488452core:RetainedEarningsAccumulatedLosses2023-11-3014488452core:AfterOneYear2024-12-012026-03-3114488452core:WithinOneYear2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:CostValuation2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-012026-03-3114488452core:Non-currentFinancialInstrumentscore:CostValuation2026-03-3114488452core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-03-3114488452core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-03-3114488452core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-03-3114488452core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-03-3114488452core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-03-3114488452core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-03-3114488452core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-03-3114488452core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-03-3114488452core:Non-currentFinancialInstrumentscore:CostValuation2024-11-3014488452core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-11-3014488452core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-11-3014488452core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-11-3014488452core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-11-3014488452core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-11-3014488452core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-11-3014488452core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-11-3014488452core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-11-3014488452bus:Director12024-12-012026-03-3114488452bus:Director22024-12-012026-03-3114488452bus:Director32024-12-012026-03-3114488452bus:Director42024-12-012026-03-3114488452bus:Director52024-12-012026-03-3114488452bus:Director62024-12-012026-03-3114488452bus:Director72024-12-012026-03-3114488452bus:Director82024-12-012026-03-3114488452bus:Director92024-12-012026-03-3114488452bus:Director102024-12-012026-03-3114488452bus:Director112024-12-012026-03-3114488452bus:Director122024-12-012026-03-3114488452bus:Director132024-12-012026-03-3114488452bus:Director142024-12-012026-03-3114488452bus:Director152024-12-012026-03-31

SOLIHULL HEALTHCARE PROPCO LIMITED

Registered Number
14488452
(England and Wales)

Unaudited Financial Statements for the Period ended
31 March 2026

SOLIHULL HEALTHCARE PROPCO LIMITED
Company Information
for the period from 1 December 2024 to 31 March 2026

Directors

ALI, Majid, Dr
BEHL, Natasha, Dr
CAUGHEY-ROGERS, Michelle Caroline, Dr
DICKINSON, Beverley Jane, Dr
FONT-OLIVE, Maria Del Mar, Dr
GANDHI, Bhavesh Ramesh, Dr
HILLMAN, Lucy Joanne, Dr
KHANNA, Sunaina, Dr
KOTECHA, Sunilkumar Babulal, Dr
LAD, Kapil Harilal, Dr
LAKHI, Nidhi, Dr
LUPOLI, Arturo, Dr
PATEL, Bilal Junaid Suleman, Dr
PATEL, Nishit Mahendrabhai, Dr
WEBB, Mark Alexander John, Dr

Registered Address

Ramsay Brown Llp The Brentano Suite
Solar House, 915 High Road
North Finchley
N12 8QJ

Registered Number

14488452 (England and Wales)
SOLIHULL HEALTHCARE PROPCO LIMITED
Balance Sheet as at
31 March 2026

Notes

31 Mar 2026

30 Nov 2024

£

£

£

£

Fixed assets
Tangible assets34,176,929-
4,176,929-
Current assets
Debtors97,769-
Cash at bank and on hand1,832,11559
1,929,88459
Creditors amounts falling due within one year5(3,688,249)(1,712)
Net current assets (liabilities)(1,758,365)(1,653)
Total assets less current liabilities2,418,564(1,653)
Creditors amounts falling due after one year6(2,469,842)-
Net assets(51,278)(1,653)
Capital and reserves
Called up share capital700100
Profit and loss account(51,978)(1,753)
Shareholders' funds(51,278)(1,653)
The financial statements were approved and authorised for issue by the Board of Directors on 23 September 2026, and are signed on its behalf by:
PATEL, Bilal Junaid Suleman, Dr
Director
Registered Company No. 14488452
SOLIHULL HEALTHCARE PROPCO LIMITED
Notes to the Financial Statements
for the period ended 31 March 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Going concern
The financial statements have been prepared on a going concern basis, the applicability of which is dependent upon the continued support of the company's creditors and financiers. At the balance sheet date, the company's liabilities exceeded its assets by £51,278 and it reported a loss of £50,225. In the opinion of the directors the company has the support of its creditors and financiers for the foreseeable future, and it is therefore considered appropriate to adopt the going concern policy.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
Finance leases and hire purchase contracts
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Related parties
For the purposes of these financial statements, a related party could be a person or an entity. Careful consideration is given to the definition of a related party to ensure that all related party relationships, transactions and balances are identified.
2.Average number of employees

20262024
Average number of employees during the year00
3.Tangible fixed assets

Land & buildings

Total

££
Cost or valuation
Additions4,176,9294,176,929
At 31 March 264,176,9294,176,929
Net book value
At 31 March 264,176,9294,176,929
At 30 November 24--
4.Investment property
Investment properties are included in the balance sheet at their open market value in accordance with the Financial Reporting Standard (FRS 102) and are not depreciated. This treatment is contrary to the Companies Act 2006 which states that fixed assets should be depreciated but is, in the opinion of the directors, necessary in order to give a true and fair view of the financial position of the company.
5.Creditors: amounts due within one year

2026

2024

££
Trade creditors / trade payables2,918-
Bank borrowings and overdrafts28,599-
Taxation and social security2,595-
Other creditors3,589,487956
Accrued liabilities and deferred income64,650756
Total3,688,2491,712
6.Creditors: amounts due after one year

2026

2024

££
Bank borrowings and overdrafts2,469,842-
Total2,469,842-
7.Obligations under finance leases
8.Financial instruments
Basic financial instruments. which include debtors and cash and bank balances. are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
9.Related party transactions
Included in other creditors due within one year is an amount of £1,795,487 (2024: £956) owed by Solihull Health Partnership. Solihull Health Partnership and the Company are connected by virtue of their common partners and directors.